Liquid Biopsy · Cancer Monitoring
What if you knew earlier?
During and after treatment, uncertainty can weigh as heavily as the illness itself. LIQOMICS liquid biopsy helps detect signs of cancer recurrence earlier with a simple blood test, giving you and your doctor the clarity you deserve.
During and After Treatment, Uncertainty Doesn't Just Go Away
The fear of cancer returning can be overwhelming. You may feel relieved once treatment is over, yet anxious about what comes next. Traditional monitoring methods often detect changes only when they are already advanced, leaving you in a fog of uncertainty. A scan can only show disease once it has grown large enough to see. You deserve clarity: early enough to act, gentle enough to live your life.
Liquid Biopsy: A New Era of Precision
LIQOMICS' advanced liquid biopsy technology offers a non-invasive way to detect signs of cancer through a simple blood test. A simple blood test that can detect signs of cancer returning, often months before a scan would show anything.
- Early Detection of Recurrence
- Personalized Treatment Insights
- Non-Invasive Monitoring (simple blood test)
- Reduced Anxiety, Greater Peace of Mind
For you, this can mean fewer burdensome examinations, more precise information for your doctor, and a greater sense of control over your health. That uncertainty shows up differently depending on where you are in your care, so here are the three questions we hear most often.
The Three Questions Most Patients Ask
Each tends to surface at a different point in your care, and a LIQOMICS blood test is designed to address them all.
"Has the treatment worked?"
By detecting or not detecting tumor-derived DNA, the test provides your doctor with molecular evidence of whether cancer is still present, even when scans appear clear.
"Will I know early if it comes back?"
Serial blood tests can often detect molecular signs of relapse months before imaging would, giving you and your doctor the advantage of time for earlier intervention.
"Am I being over- or under-treated?"
If your test is negative, unnecessary procedures may be avoided. If positive, treatment decisions can be made on molecular evidence rather than uncertainty.
How the LIQOMICS Blood Test Works
No surgery. No special preparation. Just a blood draw, analyzed by our laboratory, and a report that helps guide your next steps.
A Blood Sample Is Taken
A standard blood draw, exactly like a routine blood test. Your doctor or nurse can take it during a regular appointment. No fasting, no hospital stay.
Your Sample Is Sent to Us
The sample is analyzed in our laboratory in Cologne, Germany, using next-generation sequencing, a technology sensitive enough to detect a single cancer-related DNA fragment among millions of healthy ones.
Your Doctor Receives the Result
Within 10 to 15 working days, your doctor receives a detailed report and discusses with you what it means for your situation.
Support All Along the Way
LIQOMICS is available to you and your care team throughout. If questions arise about the test or how to interpret the result, our medical team is available to support your doctor directly.
What This Test Can Mean for Your Decisions
In many countries, molecular MRD blood tests are not yet covered by standard health insurance. The value of this test isn't in the procedure itself. It's in what the answer means for your decisions. Contact us. We can help with reimbursement claims.
The Advantage of Time
A blood test can often detect molecular signs of cancer earlier than a scan. That's the difference between treating a small early signal and a visible recurrence. Earlier detection can mean more treatment options.
Real Certainty in Both Directions
A negative result is molecular evidence that no circulating tumor DNA is detectable in your blood today. That certainty has real value and relieves the emotional burden of not knowing.
Fewer Unnecessary Procedures
Ambiguous scan results often lead to repeat imaging or further biopsies. A molecular blood test can help clarify these situations and potentially spare you unnecessary procedures.
Your Information, Your Decisions
Knowing rather than waiting and wondering gives you and your doctor more to work with for your next decision.
A Few Terms Worth Knowing
Your doctor may use these phrases when talking about a LIQOMICS blood test.
- Liquid Biopsy
- A minimally invasive test that looks for signs of cancer in a blood sample, instead of removing tissue from a tumor.
- Cell-Free DNA (cfDNA)
- Genetic material that circulates freely in the bloodstream, most of it released by healthy cells as they break down.
- Circulating Tumor DNA (ctDNA)
- The small fraction of cfDNA shed specifically by cancer cells: the signal a LIQOMICS blood test isolates to observe cancer activity without imaging.
- Minimal Residual Disease (MRD)
- Very small amounts of cancer that may remain after treatment, too few to appear on a scan, but potentially detectable in a sensitive blood test. Finding MRD early is the goal.
- Next-Generation Sequencing (NGS)
- The laboratory technology used to analyze your blood sample. It reads the genetic code of DNA fragments to identify any that match the profile of your specific cancer.
By catching these signals early, we help your medical team transition from reactive waiting to proactive monitoring, supporting earlier intervention in your care.
What a LIQOMICS Blood Test Can Show
What it means: No detectable circulating tumor DNA was found in your blood.
No tumor-derived DNA was found at the current level of sensitivity. This can provide meaningful reassurance and may support your doctor's decision to continue with standard follow-up rather than more intensive monitoring or treatment. It's reliable reassurance, not just the absence of bad news.
What it means: Circulating tumor DNA was detected in your blood.
This does not mean the cancer has returned visibly. It means your doctor now has an early molecular signal, potentially months before imaging could show anything. Earlier detection means more options. More options often lead to better outcomes.
Find the Right Monitoring Test for Your Cancer Type
Note: Our tests are specifically designed for patients currently in treatment or follow-up care. They should not be used to make a diagnosis of cancer or screen for cancer.
What cancer do you want to use our tests for?
Still not sure? Contact us for guidance ↓
LymphoVista
A specialized monitoring test for patients who have been diagnosed with lymphoma, helping you and your doctor to find out if your treatment is working and catch signs of return early.
Explore Lymphoma MonitoringCancerVista
For patients with solid tumors, giving your oncologist an earlier window into how you are responding to treatment and the chance of your cancer returning.
Explore Solid Tumor MonitoringNot Sure Yet?
If you're unsure which test is right for you, or if your specific situation isn't listed, please contact us directly. Our team is here to help guide you.
Contact Us Directly
Why LIQOMICS Was Founded
Dr. Sven Borchmann · MD, Hematology & Oncology · University Hospital Cologne
LIQOMICS was born from personal conviction: Cancer patients deserve better diagnostics and monitoring. Sven Borchmann, our founder and physician with many years of experience, witnessed firsthand the frustration of many patients. Patients asked, "Is my treatment working? Will my cancer come back?"
The solution: Leveraging cutting-edge molecular science to detect disease signals months earlier than conventional methods. In 2021, LIQOMICS was founded in Cologne, Germany, rooted in academic research, with one mission: to transform molecular understanding of cancer and its monitoring from reactive to proactive, giving patients and doctors the clarity they deserve.
Scientific & Clinical Partners
Built by Oncologists Who Understand Your Uncertainty
Ultra-Sensitive Detection
We catch microscopic signals of cancer that traditional scans often miss.
Personalized Approach
Your test is built specifically for your body's unique genetic footprint.
Non-Invasive & Safe
No hospital stay or surgery required: just a routine, painless blood test.
Fast Turnaround
Quick answers to help you and your doctor make decisions without delay.
Clinical Laboratory
Our facility operates according to strict clinical standards to ensure high accuracy and precision.
Data Residency: Germany & the EU
Your sample and results are processed exclusively in our laboratory in Cologne, Germany, under strict EU and German data protection standards (GDPR).
Common Questions
About liquid biopsy and cancer monitoring for patients.
Prepare for Your Next Doctor's Visit
Download our Patient Guide. This detailed PDF includes further information, eligibility criteria, and a list of specific questions to help you and your oncologist decide if LIQOMICS is right for your care.